Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer
| Autor: | Jingping Lin, Jieping Huang, Cuibo Lin, Jinsen Weng, Shaofeng Lin, Shen Zhang, Haizhou Ji, Chunxia Zhang, Xi Ke, Chuanpeng Dong |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Lung Neoplasms 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Biomarkers Tumor Humans Medicine Radiology Nuclear Medicine and imaging RNA Messenger Stage (cooking) Propensity Score Lung cancer Cause of death Receiver operating characteristic Proportional hazards model business.industry Gene Expression Profiling Reproducibility of Results Cancer General Medicine Gene signature medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Propensity score matching Neoplasm Recurrence Local business |
| Zdroj: | Japanese Journal of Clinical Oncology. 51:1277-1286 |
| ISSN: | 1465-3621 |
| Popis: | Background Recurrence after initial primary resection is still a major and ultimate cause of death for non-small cell lung cancer patients. We attempted to build an early recurrence associated gene signature to improve prognostic prediction of non-small cell lung cancer. Methods Propensity score matching was conducted between patients in early relapse group and long-term survival group from The Cancer Genome Atlas training series (N = 579) and patients were matched 1:1. Global transcriptome analysis was then performed between the paired groups to identify tumour-specific mRNAs. Finally, using LASSO Cox regression model, we built a multi-gene early relapse classifier incorporating 40 mRNAs. The prognostic and predictive accuracy of the signature was internally validated in The Cancer Genome Atlas patients. Results A total of 40 mRNAs were finally identified to build an early relapse classifier. With specific risk score formula, patients were classified into a high-risk group and a low-risk group. Relapse-free survival was significantly different between the two groups in both discovery (HR: 3.244, 95% CI: 2.338-4.500, P Conclusions We successfully established a reliable signature for predicting early relapse in stage I–III non-small cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|